Mesothelioma Lawsuit and New Treatments
07/25/2012 Mesothelioma Lawsuit and New Treatments: In a press release last week by Bayer HealthCare, it was publicized that a new product to treat Mesothelioma Cancer has been granted the designation of orphan drug. The new drug is a mesothelin-targeting antibody that was given this status by the U.S. Food and Drug Administration. For more information about the orphan drug designation, please visit the FDA site.
This may have no effect on those patients who have filed Mesothelioma Lawsuit cases and are in later stages of their mesothelioma diagnosis; however, it offers a hopeful prospect for those in the early stages of a Mesothelioma Cancer diagnosis.
The drug is known as BAY 94-9343and is in the midst of Phase I clinical trials in Texas, Tennessee and Maryland. The treatment will be for those individuals with advanced solid tumors according to a press release from Bayer. Previously, the prognosis for malignant mesothelioma has been very grim. New developments may fill the void for possible treatment options for Mesothelioma Cancer victims. Mesothelioma generates much legal attention since the direct cause of most all cases is exposure to asbestos fibers located on many job sites.
Mesothelioma Lawsuit cases can be pursued by the person diagnosed with Mesothelioma Cancer or by the family of the victim. Because mesothelioma is caused by direct or indirect exposure to asbestos, the defendant of the Mesothelioma Lawsuit is generally any company responsible for the asbestos exposure. Workers most likely to be exposed include construction workers, plumbers, auto mechanics, navy shipyard employees and electricians among others.
Those searching for legal representation from seasoned Mesothelioma Lawsuit attorneys can call Best Legal Source for prompt assistance. A free consultation with well-known, dependable attorneys involved in Mesothelioma Lawsuit litigation can be obtained on your behalf. Please dial (800) 611-7080 to reach the Best Legal Source helpline.
Posted in: Knock3
Leave a Reply
You must be logged in to post a comment.